MS
REGN icon

Murray Stahl’s Regeneron Pharmaceuticals REGN Stock Holding History

Murray Stahl’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Sell
645
-30
-4% -$20.4K ﹤0.01% 236
2026
Q1 		$522K Sell
675
-30
-4% -$23K 0.01% 221
2025
Q4 		$544K Sell
705
-30
-4% -$20.4K 0.01% 214
2025
Q3 		$413K Buy
735
+30
+4% +$17K 0.01% 251
2025
Q2 		$370K Sell
705
-30
-4% -$16.7K ﹤0.01% 270
2025
Q1 		$466K Hold
735
– – 0.01% 240
2024
Q4 		$524K Buy
735
+29
+4% +$24.3K 0.01% 229
2024
Q3 		$742K Sell
706
-30
-4% -$33.4K 0.01% 208
2024
Q2 		$774K Hold
736
– – 0.01% 185
2024
Q1 		$708K Buy
736
+1
+0.1% +$951 0.01% 191
2023
Q4 		$646K Sell
735
-30
-4% -$24.7K 0.01% 192
2023
Q3 		$630K Hold
765
– – 0.01% 196
2023
Q2 		$550K Hold
765
– – 0.01% 212
2023
Q1 		$629K Buy
+765
New +$577K 0.01% 197

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Murray Stahl's REGN Position: Q2 2026 in Review

Murray Stahl reduced its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2026, selling an estimated $20.4K and leaving 645 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #236.

Murray Stahl first reported a position in REGN in Q1 2023 and has held it in 14 quarters since. The position peaked at $774K in Q2 2024. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Murray Stahl held 645 shares of Regeneron Pharmaceuticals worth $402K as of Q2 2026.
  • Murray Stahl sold 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #236 holding.
  • Murray Stahl first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Murray Stahl's Regeneron Pharmaceuticals position peaked at $774K in Q2 2024.
  • 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.